From Earlier: Amgen Announces Analysis Of Rilotumumab Data Identifies A Potential Predictive Biomarker For Patients With Gastric Or Gastroesophageal Cancer
Amgen (NASDAQ: AMGN) announced yesterday results from an exploratory biomarker analysis evaluating MET expression as a predictor of clinical response to rilotumumab (AMG 102). This analysis, conducted on a previously reported Phase 2 study of rilotumumab in patients with locally advanced or metastatic gastric or gastroesophageal cancer, showed that treatment with rilotumumab in combination with chemotherapy improved median overall survival (OS) in patients whose tumors exhibited high MET protein expression.
Full results of the study will be presented in an oral presentation at the 48th Annual Meeting of the American Society of Clinical Oncology (ASCO) on June 2 (Abstract 4005, 4:45 p.m. - 5:00 p.m. CDT, E Hall D1).
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.